Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.71 |
| ▸ | DRD2 | P14416 | 6/20 | 0.71 |
| ▸ | HTR1A | P08908 | 6/20 | 0.71 |
| ▸ | DRD3 | P35462 | 5/20 | 0.71 |
| ▸ | HTR2A | P28223 | 4/20 | 0.71 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.71 |
| ▸ | HRH1 | P35367 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26382802 | 0.87 | KCNH2 (0.65) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL13103801 | 0.85 | DRD2 (0.56) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL23097718 | 0.84 | DRD2 (0.68) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL19297522 | 0.84 | SLC6A2 (0.60) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL5988317 | 0.84 | KCNH2 (0.88) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL20231608 | 0.83 | DRD2 (0.51) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL4528457 | 0.82 | KCNH2 (1.00) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL25839409 | 0.81 | MEN1 (0.55) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL155128 | 0.81 | SIGMAR1 (0.79) | SIGMAR1DRD2HTR1ADRD3HTR2A | |
| SCHEMBL29816483 | 0.81 | HTR1A (0.56) | SIGMAR1DRD2HTR1ADRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | SIGMAR1 2905/4885DRD2 4667/4885HTR1A 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.